Todos Medical Enters Exclusive Distribution Agreement with Care G.B. Plus, Ltd. for its Breast Cancer Screening Tests in Israel
May 21, 2019 at 7:59 AM EDT
REHOVOT, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF) a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders such as Alzheimer's disease , today announced the signing of a Distribution Agreement with Care G.B. Plus, Ltd. for exclusive distribution rights of Todos Medical Ltd.’s innovative and cost-effective TM-B2 blood tests for breast cancer screening in the State of Israel.
“We recently have initiated commercialization of our breast cancer screen (TM-B1) in two European markets. Today, we are proud to announce the signing of an exclusive distribution agreement with Care G.B. Plus, Ltd. for the territory of the State of Israel,” said Dr. Herman Weiss, CEO of Todos Medical. “Since inception, Todos Medical has worked diligently to bring our breast cancer screening technology to commercialization to help patients and their physicians identify cancer earlier in the disease process using a simple blood test. Today, Todos Medical has taken another step in bringing our innovative products to the general public.”
“When Todos Medical came to our attention, we knew immediately that we wanted to play a role in offering their proprietary cancer screenings for breast cancer to the Israeli public,” said Mr. Assaf Gold, CEO of Care G.B. Plus. “We look forward to working with Todos for many years to come.”
Care G.B. Plus, Ltd. will be responsible for marketing and distribution costs and execution associated with commercializing the breast cancer tests in Israel. Todos Medical will be able to use the data gathered from these initiatives to support further development and commercialization in other jurisdictions.
About Todos Medical
Todos Medical Ltd. (OTCQB: TOMDF), an Israeli company headquartered in Rehovot, is a cancer in-vitro-diagnostic (“IVD”) company engaged in the development of a series of blood tests for the early detection of a variety of cancers and has initiated the development of blood tests for neurodegenerative disorders, such as Alzheimer's disease, through Breakthrough Diagnostics, Inc. its joint venture with Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS). The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells (“PBMC”) and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU. Breakthrough Diagnostics is developing the Alzheimer’s blood diagnostic LymPro Test®.
For more information, the content of which is not part of this press release, please visit http://www.Todosmedical.com.
About Care GB Plus, Limited
Care GB Plus, an Israeli company headquartered in Tel-Aviv. Care GB Plus is an Israeli company that distributes cosmetics, para- medicinal supplements and medicinal products all over the world. The Care GB Plus team has vast experience and proven track record in distributing medical products on an international level. Care GB is well established and connected to key opinion leaders, doctors, clinics, hospitals, medical centers and has close working relationships with regulatory bodies and reimbursement agencies.
About Breakthrough Diagnostics, Inc.
Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) (80.01%) and Todos Medical Ltd (OTCQB: TOMDF) (19.99%). Breakthrough has been assigned the intellectual property and other rights to LymPro Test®, a diagnostic blood test for Alzheimer’s disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical owns an exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.
Forward-looking statements: This press release contains forward-looking statements. These forward-looking statements are only based on the current expectations of the management of Todos Medical Ltd., and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance of Todos Medical Ltd. to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical Ltd. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the company is contained under the heading “Risk Factors” in Todos Medical Ltd.’s Annual Report on Form 20-F. Reference is made to Todos Medical Ltd.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission (“SEC”) which is available on the SEC's website, www.sec.gov and in the Company’s periodic filings with the SEC.
Media Contact:
Todos Medical Ltd.
Daniel Hirsch
Investor Relations
Dan.h@todosmedical.com
(347) 699-0029
May 21, 2019 at 7:59 AM EDT
REHOVOT, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF) a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders such as Alzheimer's disease , today announced the signing of a Distribution Agreement with Care G.B. Plus, Ltd. for exclusive distribution rights of Todos Medical Ltd.’s innovative and cost-effective TM-B2 blood tests for breast cancer screening in the State of Israel.
“We recently have initiated commercialization of our breast cancer screen (TM-B1) in two European markets. Today, we are proud to announce the signing of an exclusive distribution agreement with Care G.B. Plus, Ltd. for the territory of the State of Israel,” said Dr. Herman Weiss, CEO of Todos Medical. “Since inception, Todos Medical has worked diligently to bring our breast cancer screening technology to commercialization to help patients and their physicians identify cancer earlier in the disease process using a simple blood test. Today, Todos Medical has taken another step in bringing our innovative products to the general public.”
“When Todos Medical came to our attention, we knew immediately that we wanted to play a role in offering their proprietary cancer screenings for breast cancer to the Israeli public,” said Mr. Assaf Gold, CEO of Care G.B. Plus. “We look forward to working with Todos for many years to come.”
Care G.B. Plus, Ltd. will be responsible for marketing and distribution costs and execution associated with commercializing the breast cancer tests in Israel. Todos Medical will be able to use the data gathered from these initiatives to support further development and commercialization in other jurisdictions.
About Todos Medical
Todos Medical Ltd. (OTCQB: TOMDF), an Israeli company headquartered in Rehovot, is a cancer in-vitro-diagnostic (“IVD”) company engaged in the development of a series of blood tests for the early detection of a variety of cancers and has initiated the development of blood tests for neurodegenerative disorders, such as Alzheimer's disease, through Breakthrough Diagnostics, Inc. its joint venture with Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS). The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells (“PBMC”) and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU. Breakthrough Diagnostics is developing the Alzheimer’s blood diagnostic LymPro Test®.
For more information, the content of which is not part of this press release, please visit http://www.Todosmedical.com.
About Care GB Plus, Limited
Care GB Plus, an Israeli company headquartered in Tel-Aviv. Care GB Plus is an Israeli company that distributes cosmetics, para- medicinal supplements and medicinal products all over the world. The Care GB Plus team has vast experience and proven track record in distributing medical products on an international level. Care GB is well established and connected to key opinion leaders, doctors, clinics, hospitals, medical centers and has close working relationships with regulatory bodies and reimbursement agencies.
About Breakthrough Diagnostics, Inc.
Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) (80.01%) and Todos Medical Ltd (OTCQB: TOMDF) (19.99%). Breakthrough has been assigned the intellectual property and other rights to LymPro Test®, a diagnostic blood test for Alzheimer’s disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical owns an exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.
Forward-looking statements: This press release contains forward-looking statements. These forward-looking statements are only based on the current expectations of the management of Todos Medical Ltd., and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance of Todos Medical Ltd. to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical Ltd. undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the company is contained under the heading “Risk Factors” in Todos Medical Ltd.’s Annual Report on Form 20-F. Reference is made to Todos Medical Ltd.’s Annual Report on Form 20-F for the fiscal year ended December 31, 2017 filed with the U.S. Securities and Exchange Commission (“SEC”) which is available on the SEC's website, www.sec.gov and in the Company’s periodic filings with the SEC.
Media Contact:
Todos Medical Ltd.
Daniel Hirsch
Investor Relations
Dan.h@todosmedical.com
(347) 699-0029
3
